RESUMO
Ketosis in dairy animals originates from negative energy status, associated increased absorption, and production of ketone bodies exceeding their use by the ruminants as an energy source. The present therapeutic experiment was carried out in 29 herds of Chilika buffaloes in 16 villages of three adjoining districts of Chilika Lake, Puri, Khurda, and Ganjam. Twenty Chilika buffaloes, detected positive for subclinical ketosis, were randomly selected for the study and divided into 2 groups, groups II and III, and were treated with hypertonic dextrose solution intravenously or gluconeogenic precursors along with nicotinamide orally, along with other supportive drugs in both the groups. Ten lactating Chilika buffaloes with no signs of ketosis and detected negative on Rothera test were included in the study as healthy controls (group I). Blood and milk samples were collected from all the 30 recruited buffaloes on days 0 (pre-treatment), 7, 14, and 28 for haematological and biochemical analysis. The subclinical ketosis in Chilika buffaloes did not have overt clinical signs. However, close examination revealed gradual drop in milk yield (100%), inappetence (59%), debility (46%), and uncoordinated gait (10%) without excitatory nervous signs. On day 7 following treatment, blood glucose concentration increased significantly. The mean serum triglyceride concentration of group III, treated with gluconeogenic precursors with nicotinamide, continued to decline significantly on subsequent observations. The serum enzyme activity, indicating status of liver function, declined following treatment in both the therapeutic groups. The intravenous administration of hypertonic dextrose solution compared to use of oral gluconeogenic precursors along with nicotinamide efficiently restored recovery from the subclinical ketosis in Chilika buffaloes.
RESUMO
The present experiment was carried out to assess the comparative efficacy of ivermectin and fenbendazole individually for anthelmintic therapy for the hookworm infested dogs. Dogs presented to the Department of Veterinary Clinical Medicine or Veterinary Clinical Complex, Bhubaneswar were randomly screened for Ancylostoma caninum infection and the positive dogs were selected for the therapeutic trial Faecal samples were collected randomly from presented dogs immediately after defaecation or from the rectum directly using a faecal scoop. The collected sample was examined by floatation technique to detect the positive cases of Ancylostoma caninum infection. The dogs with normal clinical parameters and no eggs or ova in the faeces were included in in group 1 (n = 12). Dogs with faecal sample positive for Ancylostoma caninum ova were recruited for the comparative study (n = 24) which were grouped into two groups consisting of 12 dogs in each (group 2 and 3). Group 2 dogs (n = 12) were treated with ivermectin at 200 µg/kg body weight once orally repeated after 15 days with proper supportive therapy each time. Group 3 (n = 12) were treated with fenbendazole at 50 mg/kg body weight once orally repeated after 15 days with proper supportive therapy each time. Haematological examinations and serum biochemical tests were carried out in all groups each time on day 0, 15 and 30 of the experiment. The therapeutic efficacy of both the drugs was calculated on the basis of number of animals found free of Ancylostoma infection as determined by reduction in EPG count of the faeces of the group following the treatment. The reduction in eggs per gram (EPG) count on day 15 and day 30 was more significant in group 2 than group 3. The mean EPG count reduced significantly to 24.17 ± 11.44 on day 15 from day 0 level of 1650.00 ± 247.25 in fenbendazole-treated dogs. On day 30, the mean value further reduced to become nil.The 15th day after treatment, mean (± SE) value of protein, albumin and globulin was changed to 5.63 ± 0.12, 2.64 ± 0.12 and 2.99 ± 0.15 g/dl, respectively. The 30th day after treatment, the values were 6.23 ± 0.14, 3.20 ± 0.18 and 3.03 ± 0.21 g/dl, respectively. The total protein and albumin values were significantly changed from day 0 level in group 2 and 3 by 15th day and 30th day, respectively, at 1% level of significance. Following treatment with ivermectin, the 15th day haematological values increased significantly at 1% level (P < 0.01) of significance. There was significant increase in the values at 1% level on the 30th day compared to day 0 and the mean values were non-significantly comparable to the healthy control group except PCV and TEC.